A Real-World, Prospective , Longitudinal, Cohort Study Analyzing comparing the efficacy and safety between generic and brand-name tofacitinib
Latest Information Update: 11 Jul 2023
At a glance
- Drugs Tofacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
Most Recent Events
- 11 Jul 2023 New trial record
- 03 Jun 2023 Primary endpoint (simplified disease activity index (SDAI) defined remission rate at month 6) has not been met, as per Results presented at the 24th Annual Congress of the European League Against Rheumatism
- 03 Jun 2023 Results presented at the 24th Annual Congress of the European League Against Rheumatism